arabinofuranosylcytosine triphosphate has been researched along with Acute Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (39.13) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowman, WP; Danks, MK; Look, AT; Ochs, J; Rivera, G; Sinkule, JA | 1 |
| Brach, MA; Herrmann, F; Mertelsmann, RH | 1 |
| Buck, SA; Gurney, JG; Matherly, LH; Ravindranath, Y; Stout, ML; Taub, JW | 1 |
| Büchner, T; Hiddemann, W; Kern, W; Schleyer, E; Unterhalt, M | 1 |
| Cao, DC; Higashigawa, M; Hori, H; Ido, M; Kawasaki, H; Sakurai, M; Shindou, K | 1 |
| Alton, P; Elgie, AW; Noordhuis, P; Peters, GJ; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Rowe, JM | 1 |
| Fukushima, T; Goto, N; Imamura, S; Iwasaki, H; Kawai, Y; Kishi, S; Masada, M; Tsutani, H; Ueda, T; Urasaki, Y; Yamauchi, T; Yoshida, A | 1 |
| Büchner, T; Hiddemann, W; Kewer, U; Reuter, C; Rolf, C; Schleyer, E; Uhrmeister, C; Unterhalt, M; Wörmann, B; Zühlsdorf, M | 1 |
| Büchner, T; Busemann, C; Hiddemann, W; Kiehl, M; Schleyer, E; Wörmann, B; Zühlsdorf, M | 1 |
| Tanaka, M | 1 |
| Busch, FW; Ehninger, G; Hiddemann, W; Jaschonek, K; Proksch, B; Schleyer, E; Schmidt, H; Schuler, U; Wanner, T | 1 |
| Arlin, Z; Bhalla, K; Grant, S; Holladay, C; Ibrado, AM; Jasiok, M | 1 |
| Jamieson, GP; Snook, MB; Wiley, JS | 1 |
| Iacoboni, S; Keating, MJ; Plunkett, W | 1 |
| Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Preisler, HD; Riva, C; Rustum, YM | 1 |
| Gahrton, G; Liliemark, JO; Paul, CY; Peterson, CO | 1 |
| Akman, SA; Joneckis, CC; Ross, DD; Schiffer, CA; Thompson, BW | 2 |
| Azarnia, N; Preisler, HD; Priore, R; Rustum, YM | 1 |
| Preisler, HD; Priore, RL; Rustum, Y | 1 |
2 review(s) available for arabinofuranosylcytosine triphosphate and Acute Disease
| Article | Year |
|---|---|
Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Cell Differentiation; Cell Division; Colony-Stimulating Factors; Cytarabine; Drug Combinations; Growth Inhibitors; Hematopoietic Cell Growth Factors; Humans; Interleukin-6; Leukemia Inhibitory Factor; Leukemia, Myeloid; Lymphokines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Concurrent use of growth factors and chemotherapy in acute leukemia.
Topics: Acute Disease; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Clinical Trials as Topic; Colony-Stimulating Factors; Growth Substances; Humans; Leukemia | 2000 |
1 trial(s) available for arabinofuranosylcytosine triphosphate and Acute Disease
| Article | Year |
|---|---|
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cells, Cultured; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged | 1987 |
20 other study(ies) available for arabinofuranosylcytosine triphosphate and Acute Disease
| Article | Year |
|---|---|
Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
Topics: Acute Disease; Adolescent; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cytarabine; Deoxycytosine Nucleotides; Drug Administration Schedule; Humans; Infusions, Parenteral; Kinetics; Leukemia; Leukemia, Lymphoid | 1984 |
Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cell Line, Transformed; Cells, Cultured; Child; Child, Preschool; Chromosomes, Human, Pair 21; Cystathionine beta-Synthase; Cytarabine; Deoxycytosine Nucleotides; Disease-Free Survival; Down Syndrome; Female; Herpesvirus 4, Human; Homocysteine; Humans; Infant; Infant, Newborn; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Methotrexate; Myelodysplastic Syndromes; Neoplastic Stem Cells; Remission, Spontaneous; Survival Rate | 1996 |
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Male | 1996 |
Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Deoxycytidine Kinase; Humans; Leukemia; Leukemia, Myeloid; Nucleic Acid Synthesis Inhibitors; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Messenger; Transcription, Genetic | 1996 |
Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.
Topics: Acute Disease; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Bryostatins; Cell Death; Cytarabine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia, Myeloid; Leukocytes, Mononuclear; Macrolides; Tetrazolium Salts; Thiazoles | 1998 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Area Under Curve; Biotransformation; Cytarabine; Female; Humans; Infusions, Intravenous; Intracellular Fluid; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prodrugs; Remission Induction; Sensitivity and Specificity; Treatment Outcome | 2001 |
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine | 1992 |
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; S Phase; Tumor Stem Cell Assay | 1992 |
Enhancement of the cytotoxicity of cytosine arabinoside by interleukin-3.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; Drug Synergism; Feasibility Studies; Humans; Interleukin-1; Interleukin-3; Leukemia, Myeloid; Tumor Stem Cell Assay | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Interactions; Etoposide; Humans; Leukemia; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Teniposide; Tumor Cells, Cultured | 1992 |
Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Kinetics; Leukemia, Myeloid; Monocytes; Recombinant Proteins; Reference Values; Stem Cells; Tumor Cells, Cultured | 1991 |
Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Binding Sites; Biological Transport; Cell Membrane; Cytarabine; Deoxycytidine Kinase; Extracellular Space; Humans; Leukemia; Lymphocytes; Nucleosides; Phosphorylation; Thioinosine; Tumor Cells, Cultured | 1990 |
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Biotransformation; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1986 |
Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
Topics: Acute Disease; Animals; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Drug Administration Schedule; Humans; Leukemia; Leukemia L1210; Metabolic Clearance Rate; Mice; Uridine Kinase | 1987 |
ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia; Male; Metabolic Clearance Rate; Middle Aged | 1987 |
Studies of ara-C metabolism in acute leukemia.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Bromodeoxyuridine; Cell Line; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia; Thymidine | 1987 |
Metabolism of ara-C by blast cells from patients with ANLL.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Leukemia; Male; Middle Aged | 1986 |
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Cytarabine; Doxorubicin; Humans; Leukemia; Middle Aged; Neoplasm Proteins; Phosphorylation; Prognosis | 1987 |
Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Phosphorylation; Time Factors | 1985 |